Skip to main content

Table 2 Germline variants with clinical significance in Chinese patients with AMPAC

From: Assessing the genomic feature of Chinese patients with ampullary adenocarcinoma: potential therapeutic targets

Patient NO.

Gender

Age

Stage

Gene

Exon

Coding seq change

Protein_change

HOM/ HET

Mutation_type

Clinical_significance

map_location

from

to

Patient014

Male

67

IV

BRCA2

11

c.6547delG

p.Glu2183fs

HET

frameshift-deletion

likely pathogenic

chr13:32915038

AG

A

Patient043

Male

66

IIB

PALB2

4

c.1317delG

p.Gly439fs

HET

frameshift-deletion

pathogenic

chr16:23646549

AC

A

Patient066

Female

47

IIIB

FANCA

4

c.367 C > T

p.Gln123Ter

HET

stopgain

likely pathogenic

chr16:89877396

G

A

Patient095

Female

74

IIIB

ATM

34

c.5170G > T

p.Glu1724Ter

HET

stopgain

likely pathogenic

chr11:108170605

G

T

Patient145

Female

66

IIB

ATM

57

c.8395_8404del

TTTCA

GTGCC

p.Phe2799fs

HET

frameshift-deletion

pathogenic

chr11:108214064

ATTTCA

GTGCC

A

Patient123

Female

50

IB

MRE11

8

c.791 C > A

p.Ser264Ter

HET

stopgain

likely pathogenic

chr11:94204794

G

T

Patient009

Male

73

IIIA

MSH6

4

c.3037_3041del

AAGAA

p.Lys1013fs

HET

frameshift-deletion

pathogenic

chr2:48028155

TGAAAA

T

Patient117

Male

76

IIIB

FANCA

32

c.3169 C > T

p.Gln1057Ter

HET

stopgain

likely pathogenic

chr16:89816208

G

A

Patient041

Male

68

IB

PALB2

4

c.246dupA

p.His83fs

HET

frameshift-insertion

likely pathogenic

chr16:23647620

G

GT

Patient132

Male

63

IIIB

MSH3

22

c.3083dupA

p.Tyr1028fs

HET

frameshift-insertion

likely pathogenic

chr5:80160713

T

TA

Patient030

Male

65

IIIB

BARD1

4

c.448 C > T

p.Arg150Ter

HET

stopgain

pathogenic

chr2:215646150

G

A

  1. HOM: Homogeneous; HET: Heterogeneous